Navigation Links
Combination therapy packs 1-2 punch against melanoma
Date:6/1/2008

DURHAM, N.C. -- Disabling a protein frequently found in melanoma tumors may make the cancer more vulnerable to chemotherapy, according to a pilot study led by researchers in the Duke Comprehensive Cancer Center.

We tested a compound that can weaken the tumor by targeting a protein found on the surface of a melanoma cell," said Douglas Tyler, M.D., a surgeon at Duke and the Durham Veterans Affairs Medical Center, and senior investigator on this study. "When chemotherapy was applied to the tumor in this weakened state it was much more effective compared to conventional therapy alone.,

The researchers presented their findings June 1 in a poster discussion session at the American Society of Clinical Oncology annual meeting in Chicago. The study was funded by Adherex Technologies, the company developing the compound that was tested in combination with chemotherapy.

Sixteen patients received the therapy as part of this study. All had been diagnosed with regionally advanced, in-transit melanoma, characterized by cancerous growths that appear and spread mainly on the limbs. This type of melanoma is often treated with regional chemotherapy, where veins and arteries are accessed in the affected area and large doses of chemotherapy are pumped directly into the body. The patients on this study received a drug known as ADH-1 both before and after chemotherapy; ADH-1 makes it difficult for cells to properly bind to one another.

Eight of the patients on the study had complete responses to therapy, meaning their tumors completely disappeared, said Georgia Beasley, M.D., a medical student at Duke and lead investigator on the study. This is very encouraging and we look forward to continuing this study and then eventually moving on to a Phase III trial.

Regional infusion of chemotherapy for melanoma is given under surgical conditions. Without ADH-1, patients generally have complete responses about 25 to 35 percent of the time.

Compared to some previous data, we have been able to double the number of complete responders to therapy by adding the ADH-1, so thats extremely promising, Beasley said.

Melanoma often affects people on their extremities, with a common scenario being a mole that appears on the foot and then spreads up the leg.

These early results really speak to the importance of developing combination therapies, Beasley said. Earlier animal results showed that using ADH-1 alone was not an effective treatment, but in combination with chemotherapy the results, both pre-clinically and clinically, have been very exciting.

The incidence of malignant melanoma is increasing at a rate faster than any other cancer, with 60,000 new cases expected to be diagnosed this year in the United States. Melanoma that has spread beyond the primary site is rarely curable, and treatment options are limited; even when it is treated, the response rates are typically poor and most people die within six to nine months.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. New combination therapy safe, promising for melanoma patients
2. Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
3. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
4. New patient satisfaction study with budesonide/formoterol combination therapy
5. New drug combination brings 1-2 punch against acute leukemia
6. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
7. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
8. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
9. Double binding sites on tumor target may provide future combination therapy
10. Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
11. Do bacterial combinations result in enhanced cytokine production? No!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... $3,296 in property taxes a year. In some states—like New York, New Jersey, ... By contrast, many overseas retirement havens have extremely low property-tax rates, which contributes ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology: